Galectin Therapeutics Inc. (GALT)

[Tesla1]

Tom: There continues to be a disconnect between the value of the company and the stock price. While there is no update from the company (so who knows how things are progressing) but the filing of the SPA could have the effect of making the phase 2 trial a registration trial. This could mean filing a new drug application (NDA) if results are positive after the completion of phase 2. So if you have 2 million people with advanced cirrhosis and the company treats just 10% of the patients per year 200,000 x $100,000 per year (let's just say $100,000 per patient), that equates to $20 Billion dollars in revenue per year. My suggestion is to just put these shares away and forget about them until the phase 2 trials have been completed. IMHO.